Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026 Results of the pivotal STAR-T study for DrugSorb®-ATR have recently been accepted for publication in a top cardiac surgery journal Management will host in-perso ...

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, ...

Core Viewpoint - Sharps Technology, Inc. is expanding its relationship with Coinbase Institutional by launching an institutional-grade validator on the Solana network, marking a significant shift from being a treasury participant to an active contributor to the network's security and decentralization [1][2]. Group 1: Company Strategy - The company will delegate a portion of its SOL treasury holdings, which currently exceed 2 million SOL, to the newly established Coinbase-operated validator [3]. - This initiative builds on the existing relationship with Coinbase Institutional, leveraging its custody, OTC, and operational infrastructure as part of the broader digital asset treasury strategy [4]. Group 2: Industry Impact - The launch of the STSS Validator positions the company as one of the first U.S.-listed firms to transition from a treasury-only approach to an active participant in blockchain development [5]. - The partnership with Coinbase aims to enhance the security, compliance, and operational reliability of institutional-grade infrastructure, reflecting the growing trend of institutions moving on-chain [5]. Group 3: Company Background - Sharps Technology is a medical device and pharmaceutical packaging company that offers patented smart-safety syringe products, focusing on ultra-low waste capabilities and incorporating advanced safety features [9]. - The company has adopted a digital asset treasury strategy centered on accumulating SOL, the native digital asset of the Solana blockchain, to generate on-chain yield [10].

Demonstrating continued revenue growth, operational efficiencies and positive cash flowMOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results ...

Core Insights - Inspire Medical Systems announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer, effective January 19, 2026 [3][4] - The company provided preliminary, unaudited revenue results for the fourth quarter and full year 2025, with fourth quarter revenue expected to be between $268.9 million and $269.1 million, representing a 12% increase year-over-year [6] - For the full year 2025, revenue is anticipated to be in the range of $911.8 million to $912.0 million, marking a 14% increase compared to 2024 [6] - Inspire's revenue guidance for 2026 is projected to be between $1,003 million and $1,013 million, indicating a growth of 10% to 11% over 2025 [2] Financial Performance - The fourth quarter revenue for 2025 is expected to show a strong performance, contributing to the overall positive momentum for the company [2] - The company experienced significant growth in the second half of 2025, particularly following the launch of the Inspire V system [2] - Inspire's revenue growth outlook for 2026 does not currently factor in potential increases from reimbursement developments [2] Leadership Changes - Matt Osberg brings over 20 years of financial leadership experience to Inspire, having previously served as CFO at Apogee Enterprises and Helen of Troy [3][4] - The appointment of Osberg is seen as a strategic move to guide the company through its next growth phase [4] Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea [8] - The company's Inspire therapy is recognized as the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [8]

Core Viewpoint - The A-share market is experiencing a significant surge, with the Shanghai Composite Index rising by 1.09%, marking a 17-day consecutive increase and reaching a new high not seen in over a decade [1]. Market Performance - The single-day trading volume exceeded 3.6 trillion yuan, setting a new historical record, indicating heightened market enthusiasm [2]. - The "AI+" concept has seen a resurgence, with sectors such as AI healthcare, AI marketing, and various AI-related concepts leading in gains. The medical device ETF (562600) rose by 2.27% today and has increased by 11.66% year-to-date [3]. Sector Analysis - The "AI+" concept has concentrated its explosive growth, with sectors like AI applications, commercial aerospace, photovoltaics, retail, and precious metals showing significant gains, while oil and coal sectors faced declines [4]. - Notable stocks in the commercial aerospace sector include Luxin Venture Capital, which has seen 10 trading limits in 12 days, and other companies like Goldwind Technology and Tongyu Communication also performed well [4]. Specific Stock Performance - In the commercial aerospace sector, stocks such as Tianrun Technology (+30.00%), Xingtou Measurement Control (+29.99%), and Liujin Technology (+29.92%) have shown remarkable increases [6]. - The photovoltaic sector has also benefited from advancements in perovskite batteries and space photovoltaic concepts, with companies like Dongfang Risheng and Maiwei Shares leading the gains [7]. AI Applications - The AI application sector has collectively strengthened, with stocks like Yidian Tianxia and Liou Shares hitting the daily limit [9]. - Recent developments in AI applications include Walmart's collaboration with Google to enhance shopping experiences through AI [11]. Future Outlook - The AI industry is shifting focus from "computing power competition" to "application value," with 2026 expected to be a pivotal year for AI applications transitioning from "technology validation" to "commercial promotion" [14]. - The medical device ETF (562600) is highlighted for its significant exposure to the brain-computer interface sector, with a 23.79% concentration in this area, making it a key investment vehicle [20]. Investment Trends - The medical device ETF has seen a net inflow of 1.31 billion yuan over the past five days, indicating strong investor interest [22]. - The Hang Seng Medical ETF (159892) is also noted for capturing the trend of Chinese biopharmaceuticals going global, with significant inflows and a 13.56% increase year-to-date [24]. Conclusion - The integration of technology and healthcare is at a critical juncture, with investment strategies focusing on quality index tools to capitalize on long-term growth opportunities in AI healthcare and brain-computer interfaces [26].

Core Insights - Zylox-Tonbridge Medical Technology Co., Ltd. is focused on building a globally competitive vascular intervention platform through R&D-driven innovation and an expanding global commercial footprint [2][4]. Group 1: Company Strategy and Innovation - The company showcased a broad portfolio of commercialized and late-stage pipeline products, emphasizing its competitive edge in neurovascular and peripheral vascular indications [3]. - Key products include the intravascular optical coherence tomography (OCT) system and the ZYLOX Pantheris atherectomy catheter, which allows real-time visualization-guided plaque removal in peripheral arteries, marking a significant advancement in precision-based interventions [3][7]. - Zylox-Tonbridge's management highlighted the integration of product innovation, manufacturing industrialization, and global commercialization as essential for scaling the business [4]. Group 2: Growth and Market Expansion - By 2025, the cumulative use of Zylox-Tonbridge products exceeded one million procedures, indicating strong physician adoption of its technologies [4]. - The company established commercial coverage in 83 countries and regions by the end of 2025 and formed strategic partnerships with over 80 distributors and commercial partners worldwide [5]. - Zylox-Tonbridge aims to strengthen its global operating platform to support continued organic growth and selective external expansion in major international medtech markets [5]. Group 3: Company Overview - Zylox-Tonbridge, founded in 2012 and headquartered in Hangzhou, China, is dedicated to the innovative research, development, manufacturing, and commercialization of medical devices in the vascular intervention field [6]. - The company adheres to the brand philosophy of "Innovation for Quality Life," aiming to provide high-quality, affordable medical devices and services to improve patients' quality of life [8].

Market Overview - The US market is experiencing significant news with the Federal Reserve being served a subpoena by Donald Trump's Department of Justice, which is perceived as a threat of criminal indictment against Jerome Powell [2][3] - This situation is expected to influence market commentary and trading, particularly affecting gold prices and NASDAQ futures [3] Company Performances - Imricor Medical Systems saw a substantial increase of nearly +20% after receiving FDA approval for its heart catheter device designed for MRI machines [4] - Light & Wonder's stock rose following the resolution of a dispute with Aristocrat Leisure over IP theft, resulting in a payment of nearly $200 million [5] - GreenX Metals' shares increased to $1 as it anticipates a payment of nearly $400 million from the Polish government in a long-running dispute [5] Declining Stocks - 4D Medical's shares are declining after a rapid increase in previous weeks, trading around $4.30 [5] - Mesoblast's stock is down approximately -5% despite posting record US revenues last week [6] - Super Retail Group's shares fell over -5% following a trading update that did not meet investor expectations [6]

Financial Sector Insights - Major banks including JPMorgan, Bank of America, and Goldman Sachs are reporting earnings this week, providing insights into consumer spending, business loan demand, and credit quality trends [1][2] - Key metrics such as net interest margins, loan loss provisions, and deposit dynamics will be critical for assessing bank conditions [1] - Investment banking revenues will shed light on M&A activity and capital markets health, while wealth management results will reflect retail investor sentiment [1] Economic Data Releases - The December CPI report is anticipated to be a significant economic release, indicating inflation trends as 2025 concludes [3] - Both headline and core CPI readings will be closely monitored for signs of inflation reacceleration, which could impact Federal Reserve policy [3] - Retail sales data will provide context on consumer demand strength, influencing pricing power and market sentiment [3] Semiconductor Sector Update - Taiwan Semiconductor's earnings will be crucial for understanding global semiconductor demand, particularly in AI and other end markets [4] - Insights on advanced node utilization and capital expenditure plans will be vital for assessing the sustainability of AI-driven chip demand [4] - TSM's commentary on competition from Samsung and Intel will provide context on industry dynamics and future investment expectations [4] Retail Sector Analysis - The NRF 2026 and ICR conferences will offer significant retailer preannouncements and guidance updates, impacting consumer discretionary sector sentiment [6] - November retail sales data will provide hard evidence of holiday shopping performance, with comparisons to conference commentary being critical for assessing retailer optimism [6] - Existing home sales data will further contextualize consumer behavior in the residential real estate market [6] Healthcare Sector Developments - The JPMorgan Healthcare Conference will gather key players in the pharmaceutical and biotech industries, generating significant news flow [7] - Updates on pipeline developments and regulatory approvals from major drugmakers could substantially influence stock movements [7] - The conference will highlight critical themes such as drug pricing pressures and innovations in oncology and gene therapy [7]

Core Viewpoint - RxSight, Inc. has announced preliminary unaudited financial and operational results for Q4 and full-year 2025, indicating a positive trajectory in patient treatment and market share despite challenges faced during the year [1][3][8]. Financial Results - Preliminary unaudited revenue for Q4 2025 is expected to be approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®), representing a 10% increase in procedure volume compared to Q3 2025 [8]. - Preliminary unaudited revenue for the full year 2025 is expected to be approximately $134.5 million, exceeding previous guidance of $125 to $130 million, with a 12% increase in procedure volume compared to 2024 [8]. - The company installed 1,134 Light Delivery Devices (LDDs) by the end of 2025, with a total of 163 LDDs sold during the year [8]. Market Position and Growth - RxSight holds approximately 10% market share in the premium intraocular lens (IOL) market, with adoption by over 25% of U.S. cataract surgeons [3]. - The company has made significant progress in treating more patients than ever before, positioning itself for sustained long-term growth [3]. Leadership Transition - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience [4][5]. - Wilterding's previous role was Senior Vice President of Global Finance for Edwards Lifesciences, where he oversaw various financial operations [5]. Future Outlook - The company is set to announce audited full-year 2025 financial results and guidance for 2026 in February 2026 [7][8].